Imugene Released Quarterly 4C Report for March Quarter 2020

  • April 27, 2020 02:11 PM AEST
  • Team Kalkine

Australia’s clinical stage immuno-oncology company, Imugene Limited (ASX:IMU) released its Quarterly 4C Report for the three-month period ended 31st March 2020. The key highlights for the March 2020 quarter include:

Gold MTF non-AMP

  • Grant of HER-Vaxx immunotherapy patent in US.
  • Completion of PD1-Vaxx GMP manufacturing.
  • Completion of PD1-Vaxx preclinical toxicology studies, which confirmed PD1-Vaxx produces high levels of PD1-targeting antibodies.
  • New publication on CF33 (Vaxinia) from Professor Yuman Fong.

With research and development expenditure of $2.2 million during the quarter, the Company reported a cash balance of $33.7 million as at 31st March 2020.

IMU traded at $0.023 on 27 April 2020 (12:59 PM AEST).


The website is a service of Kalkine Media Pty. Ltd. (Kalkine Media) A.C.N. 629 651 672. The principal purpose of the content on this website is to provide factual information only and does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stock of the company (or companies) or engage in any investment activity under discussion. We are neither licensed nor qualified to provide investment advice through this platform. In providing you with the content on this website, we have not considered your objectives, financial situation or needs. You should make your own enquiries and obtain your own independent advice prior to making any financial decisions.
Some of the images that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed on this website unless stated otherwise. The images that may be used on this website are taken from various sources on the web and are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it below the image. The information provided on the website is in good faith, however Kalkine Media does not make any representation or warranty regarding the content, accuracy, or use of the content on the website.


We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK